Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance
- PMID: 35726616
- PMCID: PMC9989728
- DOI: 10.1093/jac/dkac197
Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance
Comment in
-
Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance.J Antimicrob Chemother. 2022 Sep 30;77(10):2895-2896. doi: 10.1093/jac/dkac277. J Antimicrob Chemother. 2022. PMID: 35971761 Free PMC article. No abstract available.
-
'Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance'-authors' response.J Antimicrob Chemother. 2022 Oct 28;77(11):3212. doi: 10.1093/jac/dkac330. J Antimicrob Chemother. 2022. PMID: 36177772 No abstract available.
References
-
- Patel G, Huprikar S, Factor SHet al. . Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29: 1099–106. - PubMed
-
- Tamma PD, Aitken SL, Bonomo RAet al. . Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis 2021; 72: e169–83. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous